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Abstract
Background: Hormone-refractory prostate cancer (HRPC) is characterized by poor response to
chemotherapy and high mortality, particularly among African American men when compared to
other racial/ethnic groups. It is generally accepted that docetaxel, the standard of care for
chemotherapy of HRPC, primarily exerts tumor cell death by inducing mitotic catastrophe and
caspase-dependent apoptosis following inhibition of microtubule depolymerization. However,
there is a gap in our knowledge of mechanistic events underlying docetaxel-induced caspase-
independent cell death, and the genes that antagonize this process. This knowledge is important for
circumventing HRPC chemoresistance and reducing disparities in prostate cancer mortality.
Results: We investigated mechanistic events associated with docetaxel-induced death in HRPC
cell lines using various approaches that distinguish caspase-dependent from caspase-independent
cell death. Docetaxel induced both mitotic catastrophe and caspase-dependent apoptosis at various
concentrations. However, caspase activity was not essential for docetaxel-induced cytotoxicity
since cell death associated with lysosomal membrane permeabilization still occurred in the
presence of caspase inhibitors. Partial inhibition of docetaxel-induced cytotoxicity was observed
after inhibition of cathepsin B, but not inhibition of cathepsins D and L, suggesting that docetaxel
induces caspase-independent, lysosomal cell death. Simultaneous inhibition of caspases and
cathepsin B dramatically reduced docetaxel-induced cell death. Ectopic expression of lens
epithelium-derived growth factor p75 (LEDGF/p75), a stress survival autoantigen and transcription
co-activator, attenuated docetaxel-induced lysosomal destabilization and cell death. Interestingly,
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LEDGF/p75 overexpression did not protect cells against DTX-induced mitotic catastrophe, and
against apoptosis induced by tumor necrosis factor related apoptosis inducing ligand (TRAIL),
suggesting selectivity in its pro-survival activity.
Conclusion: These results underscore the ability of docetaxel to induce concomitantly caspase-
dependent and independent death pathways in prostate cancer cells. The results also point to
LEDGF/p75 as a potential contributor to cellular resistance to docetaxel-induced lysosomal
destabilization and cell death, and an attractive candidate for molecular targeting in HRPC.
Introduction
Prostate cancer (PCa) is the most frequently diagnosed
cancer in men and the second leading cause of male can-
cer deaths in the U.S. [1]. PCa also presents the greatest
racial disparity of any cancer in the U.S., with higher inci-
dence and mortality in African-American men (AA), com-
pared to other ethnic groups [2,3]. A factor contributing to
these disparities is the more aggressive and perhaps more
therapy-resistant form of the disease observed among AA
men [2,3]. Understanding the underlying causes of this
increased tumor aggressiveness would require a multi-
prong approach that includes evaluation of potential
racial/ethnic differences in prostate tumor biology, identi-
fication of gene-environment interactions leading to pros-
tate inflammation, elucidation of molecular mechanisms
associated with PCa chemoresistance, and development
of more effective therapeutic interventions for HRPC.
Docetaxel (DTX, Taxotere®), a semi-synthetic analog of
paclitaxel, has emerged in recent years as the standard of
care for chemotherapy of HRPC [4]. Unfortunately, most
HRPC patients treated with DTX ultimately manifest
resistance to the drug and succumb to the disease. The
mechanisms underlying resistance to DTX in HRPC
appear to be diverse and poorly understood; however, a
growing body of evidence implicates cellular anti-apop-
totic, stress, and redox signaling pathways in the develop-
ment of HRPC and DTX resistance [5-10]. Attaining a
mechanistic understanding of DTX-induced cell death
and DTX resistance in PCa would facilitate the identifica-
tion of new molecular targets and the development of
rational therapeutic strategies aimed at sensitizing HRPC
to this and other anti-tumor drugs.
It is generally accepted that DTX primarily exerts tumor
cell death by inducing mitotic catastrophe and caspase-2
and -3-dependent apoptosis following inhibition of
microtubule depolymerization [11-16]. DTX has also
been reported to induce non-apoptotic death in tumor
cells, both in vitro and in vivo, depending on the dose, cell
type, and tumor microenvironment [11,15,17]. While
mechanistic insights into non-apoptotic, caspase-inde-
pendent cell death induced by paclitaxel have been
reported [18,19], knowledge of mechanistic events under-
lying DTX-induced caspase-independent cell death is very
scarce. Caspase-dependent and independent cell death
pathways co-exist in tumor cells and can be triggered in
parallel by therapeutic agents [20-22]. While most efforts
in targeting cellular survival pathways have focused on
inactivating proteins that antagonize caspase-dependent
pathways, there is growing consensus that targeting sur-
vival proteins that antagonize caspase-independent or
non-apoptotic cell death might be a promising strategy for
increasing the effectiveness of chemotherapeutic drugs
[20-22].
The lens epithelium derived growth factor p75 (LEDGF/
p75) is emerging as a stress response protein that pro-
motes cell survival against death induced by stressors such
as oxidative stress, heat shock, serum starvation, and
chemotherapy [23-28]. This protein is also known as tran-
scription co-activator p75 (TCP75), PC4 and SFRS1 inter-
acting protein (PSIP), and dense fine speckled
autoantigen of 70 kD (DFS70) [29-31]. LEDGF/p75 has
been identified as a member of the hepatoma-derived
growth factor family [32], a NUP98-fusion protein result-
ing from chromosomal translocations in leukemias [33],
an autoantigen in diverse autoimmune and inflammatory
conditions [30,34-36], and a key cellular co-factor for the
chromosomal integration of HIV-1 [37-39]. LEDGF/p75
is presumed to promote malignant transformation and
resistance to stress-induced cell death via either direct
binding to promoter regions of stress survival and anti-
oxidant genes, or protein-protein interactions leading to
transcriptional activation of cancer-related genes [40-42].
The stress-survival activity of LEDGF/p75 appears to be
regulated by alternative splicing resulting in the removal
of its carboxyl C-terminal domain, and by caspase-medi-
ated disruption of both its amino (N) and C-terminal
domains [25,43].
We reported previously that LEDGF/p75 is the target of
autoantibody responses in some patients with PCa, and
that its expression is upregulated in advanced stage PCa
[44]. LEDGF/p75 expression was also found elevated in
human breast and bladder carcinomas, and its ectopic
overexpression increased the tumorigenic potential of
human cancer cells in murine models [27]. In this study
we provide evidence that treatment of HRPC cells with
DTX, in addition to inducing mitotic catastrophe and cas-Molecular Cancer 2009, 8:68 http://www.molecular-cancer.com/content/8/1/68
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pase-dependent apoptosis, induces a caspase-independ-
ent cell death pathway that involves lysosomal
destabilization and cathepsin B activation. We also show
that ectopic overexpression of LEDGF/p75 attenuates
DTX-induced lysosomal destabilization and cell death,
but not DTX-induced mitotic catastrophe or apoptosis
induced by tumor necrosis factor related apoptosis induc-
ing ligand (TRAIL). These results underscore the ability of
DTX to activate multiple cell death pathways, and point to
LEDGF/p75 as a potential contributor to DTX resistance
in PCa.
Materials and methods
Cell Lines, Antibodies, and Reagents
PC3, DU145 and RWPE-2 cell lines were obtained from
American Type Culture Collection (ATCC) and cultured
according to ATCC recommendations. The following anti-
bodies were used: mouse monoclonal anti-poly (ADP-
ribose) polymerase (PARP) AB-2 (Calbiochem), mouse
monoclonal anti-β-actin (Sigma-Aldrich), goat polyclonal
anti-cathepsin B (Santa Cruz Biotechnology), and horse-
radish peroxidase (HRP)-labeled secondary IgG antibod-
ies (Zymed). Human autoantibodies to LEDGF/p75 were
a kind gift from Dr. Edward Chan (University of Florida,
Gainesville). The broad caspase inhibitor benzylocarbo-
nyl-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-FMK) and
the specific caspase-2 inhibitor N-acetyl-Val-Asp-Val-Ala-
Asp-aldehyde (Ac-VDVAD-CHO) were purchased from
Biomol International. DTX was purchased from LC Labo-
ratories. Recombinant human TRAIL and actinomycin D
were purchased from R&D Systems. Staurosporine (STS),
N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin
(Ac-DEVD-AMC, fluorogenic caspase-3/7 substrate), and
Ac-VDVAD-AMC (fluorogenic caspase-2 substrate) were
purchased from Axxora. Inhibitors of cathepsin B (CA-
074Me), cathepsin L (cathepsin L inhibitor I) and cathep-
sin D (pepstatin A) were obtained from EMD Biosciences.
The cathepsin B fluorogenic substrate Magic Red MR-
(RR)2, Acridine Orange (AO), and Hoescht 33342 were
purchased from Immunochemistry.
Induction of Cell Death
Cell death was induced by treatment with DTX (various
concentrations), TRAIL/actinomycin D (100 ng/ml each),
or 4 μM STS for up to 48 h. In some experiments cells were
preincubated with either 100 μM of Z-VAD-FMK, 100 μM
of Ac-VDVAD-CHO, 100 μM cathepsin B inhibitor, 150
μM cathepsin L inhibitor, or 100 μM cathepsin D inhibi-
tor for 1 h prior to exposure to the cytotoxic drugs. Cells
were visualized on an Olympus IX70 microscope
equipped with Hoffmann Modulation Contrast (Olym-
pus American). Images were acquired using a digital Spot
Imaging System (Diagnostic Instruments).
Cell Viability Assays
Cells seeded in 96-well plates (104 cells per well) were
treated with cytotoxic drugs in the presence and absence
of inhibitors, washed with phosphate buffered saline
(PBS), and fixed in 4% paraformaldehyde for 1 h at 4°C.
Cells were then washed three times with distilled water,
and Accustain Crystal Violet solution (Sigma-Aldrich)
(1:4) was added to each well followed by incubation for
20 minutes at room temperature. Plates were washed with
distilled water to remove excess dye and then dried at
room temperature. Acetic acid (10% v/v) was added to
each well for 10 minutes and absorbance was measured at
570 nanometers (nm) using a μQuant microplate reader
(Bio-tek Instruments). Cell viability was also determined
using a modified (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Sigma-
Aldrich, St. Louis, MO). Briefly, cells were seeded in 96-
well plates (104 cells per well) and then treated with cyto-
toxic drugs in the presence and absence of inhibitors. MTT
was then added to each well (final concentration, 1 mg/
ml) and plates were incubated in a 5% CO2 incubator at
37°C for 1 h. Plates were centrifuged at 2,000 rpm for 30
minutes to avoid loss of floating cells. Supernatants were
discarded and 150 μl of dimethyl sulfoxide (DMSO), were
added to each well. Absorbance was measured at 450 nm.
Caspase Activity Assays
Caspase activity assays were performed as described previ-
ously [43]. Briefly, cells were seeded in black, clear-bot-
tomed 96-well plates (104  cells per well). At the
conclusion of treatment with cytotoxic drugs in the pres-
ence and absence of inhibitors, cells were incubated with
50 μl of 3× caspase buffer [150 mM Hepes pH 7.4, 450
mM sodium chloride, 150 mM potassium chloride, 30
mM magnesium chloride, 1.2 mM ethylene glycol-bis(2-
aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA),
30% sucrose, 10% CHAPS, and 1.5% NP-40], 30 mM
dithiothreitol (DTT), 3 mM phenylmethanesulphonylflu-
oride (PMSF), and 75 μM of the fluorogenic peptide sub-
strates Ac-DEVD-AMC (caspase-3/7) or Ac-VDVAD-AMC
(caspase-2) for 2 h at 37°C, followed by incubation at
room temperature for 12 h. In these experiments, TRAIL/
actinomycin D treatment was used as a control for cas-
pase-3/7 activation, whereas STS was used as a control for
caspase-2 activation. Absorbance was then read in a
FLX800 Microplate Fluorescent Reader (Bio-tek Instru-
ments) at excitation of 360 nm and emission of 460 nm.
Fold activity was determined by normalizing to one the
absorbance values for untreated cells.
Immunoblotting
Equal amounts of protein from whole cell lysates were
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), blotted onto polyvinyl dif-Molecular Cancer 2009, 8:68 http://www.molecular-cancer.com/content/8/1/68
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luoride (PVDF) membranes, and analyzed by immunob-
lotting as described previously [25].
Analysis of Mitochondrial Membrane Potential (MMP)
Cells (3 × 105 per well) were grown in 6-well plates. After
treatment with DTX, 7.5 μl of 5,5',6,6'-tetrachloro-
1,1',3,3'-tetraethyl-benzimidazoly-carbocyanine iodide
(JC-1, stock: 5 mg/ml) were added per ml to each well, fol-
lowed by incubation at 37°C for 30 minutes. Floating
cells were collected and combined with cells harvested by
trypsinization. JC-1 retained in 20,000 cells was measured
at 530 nm (FL-1, green) and 590 nm (FL-2, red) using a
FACScalibur flow cytometer (BD Biosciences). CellQuest
Pro software was used for data analysis.
Flow Cytometric Cell Cycle Analysis
Cells (3 × 105 per well) were grown in 6-well plates. After
treatment with DTX, floating cells were collected and later
combined with attached cells harvested by trypsinization.
Cells were resuspended in PBS, fixed with 2 ml of ice-cold
70% ethanol, and incubated for 30 minutes at 4°C. Cell
pellets were collected by centrifugation (5,000 rpm for 5
minutes) and resuspended in 400 μl of PBS, 50 μl of pro-
pidium iodide (PI) solution (0.6 mM) and 50 μl of RNase
A (1 mg/ml). After incubation for 30 minutes in the dark
at 37°C, cells were analyzed for DNA content using a FAC-
Scalibur flow cytometer. Fluorescence from the PI-DNA
complex was estimated on a minimum of 50,000 cells per
sample and analyzed with CellQuest Pro software.
Analysis of Lysosomal Membrane Permeabilization
The Acridine Orange (AO) method was used to analyze
lysosomal membrane permeabilization (LMP) as
described previously [45]. Briefly, cells growing in 6-well
culture plates were exposed to AO (5 μg/ml) and counter-
stained with Hoescht 33342 (1 μg/ml) for 20 minutes at
37°C. Cells were then examined under an Olympus BX50
epifluorescence microscope using a UMPlanPI 60X/
0.90W water immersion objective (Olympus). Images
were acquired using a digital Spot camera system (Diag-
nostic Instruments).
Cathepsin B Activity Assay
Cathepsin B activity was detected using the fluorogenic
susbtrate Magic Red MR-(RR)2 (Immunochemistry Tech).
Briefly, cells growing in 6-well culture plates were exposed
for 1 hour to the cathepsin B substrate, rinsed twice with
PBS, and counterstained with 1 μg/ml of Hoechst 33342
for nuclear visualization. Cells were directly examined
under an Olympus BX50 epifluorescence microscope
using a UMPlanPI 60X/0.90W water immersion objective.
Images were acquired using a digital Spot camera system.
Generation of Cell Lines Stably Overexpressing LEDGF/
p75
The LEDGF/p75 cDNA was previously cloned into the
mammalian expression vector pcDNA3.1+ (Invitrogen)
[25]. Both the pcDNA3.1+ empty vector and pcDNA3.1+/
LEDGF/p75 vector were transfected into PC3 cells using
the Fugene 6 method (Roche). Forty-eight hours post-
transfection, cells were trypsinized and seeded into 6-well
plates. Selection of stable transfectants was achieved by
adding G418 (Fisher Scientific) to the cell cultures. Colo-
nies were expanded and assayed for increased expression
of LEDGF/p75 by immunoblotting. Clones overexpress-
ing LEDGF/p75 were selected for further expansion and
stored in liquid nitrogen.
Real-Time PCR
Total RNA was extracted from PC3 cells with TRIzol Rea-
gent (Invitrogen), and single-strandedcDNA was con-
structed using Superscript III polymerase (Invitrogen) and
oligo-dT primers. Real-time polymerase chain reaction
(RT-PCR) was performed using the iCycler (Bio-Rad) and
SYBR Green PCR master-mix reagents (Abgene). The fol-
lowing primers were used: LEDGF/p75 forward 5'-
TCAAGTCAACAGGCAGCAAC-3'; LEDGF/p75 reverse 5'-
TAGCTGCAGGTCGTCCTCTT-3'; Cofilin (CFL) forward
5'-AAGTCTTCAACGCCAGAGG A-3'; CFL reverse 5'-
GGCCCAGAAGATAAACACCA-3'. Primers were used at a
concentration of 4 μM.
Results
DTX-induced cell death involves caspase-activation but is 
not entirely caspase-dependent
To determine whether DTX-induced cytotoxicity in PCa
cells is dependent on the activation of caspases, particu-
larly caspase-2, we first examined the activity of caspases-
2 and -3 in the hormone-refractory PCa cell lines PC3,
DU145, and RWPE-2 after treatment with increasing DTX
doses, ranging from 0.01 μM to 5 μM. Since the observed
results for these and some subsequent experiments were
relatively similar with all the doses and cell lines, and for
the sake of brevity, we opted to show only data for PC3
cells treated with relatively low (0.1 μM) and high (3 μM)
concentrations. These correspond to plasma DTX concen-
trations achieved in treated PCa patients during the initial
hours post-infusion [12,46].
Both concentrations of DTX induced gradual activation of
caspases-2 and 3 during treatment of PC3 cells for up to
48 h (Fig. 1A). STS and TRAIL were used as controls for
caspase-2 and caspase-3 activation, respectively (Fig. 1A).
Caspase-2 activity was abolished by pre-treatment of cells
with the specific inhibitor Ac-VDVAD-CHO, whereas both
caspases were completely inhibited with the broad-cas-
pase inhibitor Z-VAD-FMK (Fig. 1A). In light of this, most
subsequent experiments were conducted only in the pres-Molecular Cancer 2009, 8:68 http://www.molecular-cancer.com/content/8/1/68
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Figure 1 (see legend on next page)
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ence of Z-VAD-FMK. We observed that the caspase sub-
strates PARP and LEDGF/p75 [25] were cleaved into their
signature apoptotic fragments of p85 and p65, respec-
tively, during DTX-induced PC3 cell death (Fig. 1B). How-
ever, no cleavage was observed in the presence of Z-VAD-
FMK, consistent with inhibition of caspase activity.
To further highlight the importance of the caspase-
dependent pathway in DTX-induced PC3 cell death we
analyzed the effect of DTX on mitochondrial membrane
potential (MMP). Loss of MMP was induced at both con-
centrations of DTX after 48 h of exposure to the drug, and
was inhibited by Z-VAD-FMK, confirming its dependence
on caspase activation (Fig. 1C). We also measured DNA
fragmentation by flow cytometric analysis of DNA con-
tent. As observed in Fig. 1D, treatment with either 0.1 or
3.0 μM DTX for 48 h led to significant increase in the
subG1 cell population. In the presence of Z-VAD-FMK
there was a decrease in the subG1 cell population con-
comitant with increase in the G2/M fraction. Taken
together, the data presented in Fig. 1 indicate that both
low and high doses of DTX induce caspase activation, cas-
pase substrate cleavage, loss of MMP, and DNA fragmen-
tation. In addition to these events, we also observed that
DTX induced reactive oxygen species (ROS) in PC3 cells
(data not shown), consistent with a previous report [47].
To explore the possibility that DTX-induced cell death in
PCa cells may also involve a caspase-independent path-
way, we first determined whether caspase inhibition
would prevent the death of drug-treated PC3 cells. Both
low and high concentrations of DTX reduced cell viability
as measured by crystal violet staining (Fig. 2A). However,
this reduction was only partially abrogated in the presence
of the caspase inhibitors Z-VAD-FMK and Ac-VDVAD-
CHO, suggesting that a caspase-independent pathway was
also activated by DTX. Similar results were observed in
DU145 and RWPE-2 cells (data not shown). To confirm
that the loss of viability measured in DTX-treated PC3
cells with the crystal violet method was not merely the
result of cell rounding and detachment associated with
mitotic arrest, we also measured cell viability using a
modified MTT method that avoided loss of floating cells,
with similar results (Fig. 2B). Consistent with these
results, morphological analysis revealed the presence of
both rounded and dead cells after treatment with DTX for
up to 48 h in the presence of caspase inhibitors (Fig. 2C).
However, most cells treated with TRAIL in the presence of
caspase inhibitors were still attached and did not display
apoptotic morphology (Fig. 2C).
DTX-induced PC3 cell death involves lysosomal membrane 
permeabilization
We evaluated the possibility that DTX might activate the
lysosomal cell death pathway concomitant with activa-
tion of the caspase-dependent pathway. The acridine
orange (AO) method was used to assess lysosomal mem-
brane permeabilization (LMP) in PC3 cells after treatment
with 0.1 or 3.0 μM DTX for up to 48 h. Both concentra-
tions of DTX induced extensive AO leakage into the
cytosol, producing a diffuse yellow color (Fig. 3A). This
was visible mostly in detached cells and was not caspase-
dependent since it could not be inhibited by Z-VAD-FMK
(Fig. 3A), Ac-VDVAD-CHO (data not shown), or the com-
bination of both inhibitors (data not shown). The
attached cells still had intact lysosomes (as visualized by
punctuated cytoplasmic red AO staining) but appeared to
undergo mitotic catastrophe, as evidenced by the presence
of multinucleation (Fig. 3A).
LMP is typically associated with release and activation of
cathepsins, particularly cathepsins B, D and L [48,49]. To
investigate the involvement of these cathepsins in DTX-
induced PC3 cytoxicity, we evaluated whether their inhi-
bition attenuated cell death. For these experiments, PC3
cells were pre-incubated with cathepsin B inhibitor (CA-
74Me), cathepsin D inhibitor (pepstatin A), or cathepsin
L inhibitor (Cathepsin L inhibitor) prior to exposure to
DTX. Inhibition of cathepsins D and L had no effect on
PC3 cell viability in the presence of low and high doses of
Docetaxel (DTX) induces caspase-dependent death in PC3 cells Figure 1 (see previous page)
Docetaxel (DTX) induces caspase-dependent death in PC3 cells. A. Caspase-3/7 and -2 activity assays in PC3 cells 
treated with DTX, TRAIL, or STS in the presence and absence of the pan caspase inhibitor Z-VAD-FMK and the caspase-2 
inhibitor Ac-VDVAD-CHO respectively. Cells were pre-treated 1 h prior to drug treatment. Activity was determined by 
measuring the cleavage of the fluorogenic substrate Ac-DEVD-AMC for caspase-3/7 and Ac-VDVAD-AMC for caspase-2. Fold 
activation was determined by normalization of the test sample to untreated controls: B. Immunoblotting analysis of PARP and 
LEDGF/p75 cleavage in DTX-treated PC3 cells in the presence and absence of Z-VAD-FMK: C. Flow cytometric analysis of 
mitochondrial membrane potential (MMP), using the JC-1 method, in PC3 cells treated with DTX in the presence and absence 
of Z-VAD-FMK for 48 h. A representative of three independent experiments is shown: D. Cell cycle analysis of PC3 cells 
treated with DTX in the presence and absence of Z-VAD-FMK for 48 h. Flow cytometric analysis of cells stained with propid-
ium iodide was used to determine the percentage of cells in SubG1 and G2/M. Representative DNA histograms are shown. 
Error bars in panels A and D represent the standard deviation of at least three independent experiments done in triplicates (* 
p < 0.05, t-test).Molecular Cancer 2009, 8:68 http://www.molecular-cancer.com/content/8/1/68
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Inhibition of caspases does not block DTX-induced cytotoxicity in PC3 cells Figure 2
Inhibition of caspases does not block DTX-induced cytotoxicity in PC3 cells. A. Percentage of surviving PC3 cells 
treated with DTX in the presence and absence of Z-VAD-FMK, AC-VDVAD-CHO, or both inhibitors. Cells were pre-treated 
with the inhibitors 1 h before exposure to DTX. Cell viability was determined by crystal violet staining. Absorbance was meas-
ured at 570 nm and the values were normalized against those of untreated cells, which were assumed to be 100% viable. Errors 
bars represent the standard deviation of at least three independent experiments done in triplicate (*p < 0.05 compared to 
untreated, t-test): B. Same as in panel A except that cell viability was measured using the MTT assay. Errors bars represent the 
standard deviation of two independent experiments done in hexuplicates (*p < 0.05 compared to untreated, t-test): C. Mor-
phological analysis of PC3 cells treated as indicated above for 48 h. Cells were visualized on an Olympus IX70 inverted micro-
scope equipped with Hoffmann Modulation Contrast.
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Figure 3 (see legend on next page)
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DTX. However, inhibition of cathepsin B significantly
increased cell viability (Fig. 3B).
To determine if cathepsin B is released from the lysosomes
after treatment of PC3 cells with DTX, a cathepsin B activ-
ity assay was performed in which changes in the intracel-
lular localization of the activity of this protease were
examined by fluorescence microscopy. Cathepsin B activ-
ity was detected using the fluorogenic substrate Magic Red
MR-(RR)2. This substrate fluoresces once cleaved by cathe-
psin B. Untreated cells displayed red fluorescence mostly
localized to the lysosomes (Fig. 3C). However, cells
treated with 0.1 or 3 μM DTX for 36 h displayed diffuse
red fluorescence, indicative of cathepsin B activity in the
cytosol, most likely resulting from LMP. In the presence of
cathepsin B inhibitor there was red fluorescence localized
inside the lysosomes in the majority of DTX-treated cells,
consistent with attenuation of LMP during DTX-induced
cell death. The detection of this red fluorescence also indi-
cated that the inhibitor did not block completely cathep-
sin B activity.
Simultaneous inhibition of caspases and cathepsin B 
antagonizes DTX-induced cell death
In light of the above results indicating attenuation of DTX-
induced cell death by inhibition of cathepsin B, we sought
to explore whether blocking cathepsin B activity was suffi-
cient to delay LMP in DTX-treated PC3 cells. Staining of
PC3 cells with AO after exposure to DTX and cathepsin B
inhibitor for 36 h revealed that while LMP was not as
prominent as observed in DTX-treated cells in the absence
of inhibitor, there were still yellow cells present, indicat-
ing that inhibition of cathepsin B did not confer full pro-
tection against DTX-induced cell death (Fig. 4A, compare
with Fig. 3A). Since cathepsin B can induce nuclear frag-
mentation upon release from lysosomes [48], we also
examined the effects of cathepsin B inhibition on DNA
fragmentation. Inhibition of cathepsin B partially pro-
tected against DTX-induced DNA fragmentation, as
inferred by the reduction of the subG1 cell population in
cultures treated with cathepsin B inhibitor (Fig. 4B). These
findings were consistent with the partial protection con-
ferred by cathepsin B inhibitor against DTX-induced cyto-
toxicity (Fig. 3B).
To determine if both caspases and cathepsin B contribute
to LMP, we treated PC3 cells with 0.1 or 3 μM DTX for 36
h in the presence of both Z-VAD-FMK and cathepsin B
inhibitor. Interestingly, LMP was markedly decreased in
cells treated with both inhibitors, as inferred by the reduc-
tion in the number of yellow cells (Fig. 4C). Furthermore,
DTX-induced DNA fragmentation was abolished in the
presence of both inhibitors (Fig. 4D). We followed the
survival of cells treated with DTX in the presence of both
Z-VAD-FMK and cathepsin B inhibitor for up to 7 days
and noticed that the majority of cells survived as long as
both inhibitors were added freshly to cell cultures every
36 h (data not shown). We also observed that inhibition
of cathepsin B led to decreased caspase activity, suggesting
that LMP and cathepsin activation are upstream events
that influence caspase activation (data not shown). Taken
together, these results indicated that caspases and cathep-
sins, particularly cathepsin B, play a concerted role during
DTX-induced cytotoxicity.
Overexpression of LEDGF/p75 attenuates DTX-induced 
cell death
In light of a recent report suggesting that LEDGF/p75 pro-
motes lysosomal stabilization in response to cytotoxic
drugs [27], we investigated whether its ectopic expression
in PC3 cells would antagonize DTX-induced cytotoxicity
and LMP. For these experiments, we generated cell lines
stably overexpressing LEDGF/p75 (Fig. 5A). Clones stably
expressing LEDGF/p75 displayed increased resistance to
0.1 or 3 μM DTX, when compared to clones transfected
with empty pcDNA vector (Fig. 5B). Interestingly, LEDGF/
p75 expression did not attenuate TRAIL-induced cell
death (Fig. 5B). Consistent with these results, ectopic
expression of LEDGF/p75 was also observed to protect
RWPE-2 cells against DTX-induced cell death but not
DTX induces lysosomal membrane permeabilization (LMP) in PC3 cells Figure 3 (see previous page)
DTX induces lysosomal membrane permeabilization (LMP) in PC3 cells. A. Determination of lysosomal integrity in 
PC3 cells treated with DTX for 24 hours in the presence and absence of Z-VAD-FMK. Cells were exposed to acridine orange 
(AO) for lysosome visualization under fluorescence microscopy. Untreated cells showed localized granular red fluorescence 
corresponding to staining of intact lysosomes. Cells that detached after treatment with DTX in the presence and absence of Z-
VAD-FMK displayed increased yellow fluorescence indicative of LMP. Most cells that remained attached after treatment 
appeared to have intact lysosomes but exhibited multinucleation. Hoescht staining was used to visualize nuclear morphology: 
B. Cathepsin B inhibitor (CBI) but not inhibitors of cathepsin L (CLI) or cathepsin D (CDI) attenuated cell death induced by 0.1 
μM DTX (top set of graphs) and 3 μM DTX (bottom set of graphs), as assessed by crystal violet viability assays. Errors bars 
represent the standard deviation of at least three independent experiments done in triplicate (*p < 0.05, t-test): C. Detection 
of intracellular cathepsin B activity in PC3 cells using the fluorogenic substrate Magic Red MR-(RR)2. Cells treated with DTX 
for 36 hours showed diffuse cathepsin B activity (red fluorescence), whereas the activity in untreated cells and cells treated 
with DTX in the presence of CBI was localized mainly to lysosomes.Molecular Cancer 2009, 8:68 http://www.molecular-cancer.com/content/8/1/68
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against TRAIL or STS-induced cell death (data not shown).
Morphological analysis of stable transfectants exposed to
DTX for 48 h showed less cell rounding and death in cul-
tures of PC3 cells overexpressing LEDGF/p75 (Fig. 5C).
Also, flow cytometric cell cycle analysis revealed a reduc-
tion in the percentage of subG1 cells in DTX-treated cul-
tures, consistent with a decrease in the levels of DNA
fragmentation (Fig. 5D). However, overexpression of
LEDGF/p75 did not abrogate the ability of DTX to induce
mitotic arrest, as indicated by the increase in the G2/M
fraction in cells treated with 0.1 or 3 μM DTX (Fig. 5D).
Simultaneous inhibition of caspases and cathepsin B attenuates DTX-induced cell LMP and DNA fragmentation Figure 4
Simultaneous inhibition of caspases and cathepsin B attenuates DTX-induced cell LMP and DNA fragmenta-
tion. A. PC3 cell cultures treated with DTX for 36 hours in the presence of cathepsin B inhibitor and stained with acridine 
orange (AO) appeared to have less detached yellow cells than cultures treated with DTX in the absence of inhibitor (compare 
with Fig. 3A). Images were acquired from fields that had both attached and detached cells: B. Cell cycle analysis of PC3 cells 
treated with DTX in the presence and absence of cathepisn B inhibitor for 48 h. Flow cytometric analysis of cells stained with 
propidium iodide was used to determine the percentage of subG1 cells. Error bars represent the standard deviation of at least 
three independent experiments (* p < 0.05, t-test). Representative DNA histograms for one of the experiments are shown: C. 
PC3 cell cultures treated with DTX for 36 hours in the presence of both Z-VAD-FMK and cathepsin B inhibitor, and stained 
with acridine orange, showed very few yellow detached cells, as compared with cultures treated with DTX in the absence of 
inhibitors (see Fig. 3A): D. Cell cycle analysis of PC3 cells treated with DTX in the presence and absence of Z-VAD-FMK and 
cathepisn B inhibitor for 48 h. Flow cytometric analysis of cells stained with propidium iodide was used to determine the per-
centage of subG1 cells. Error bars represent the standard deviation of at least three independent experiments (* p < 0.05, t-
test). Representative DNA histograms for one of the experiments are shown.
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Figure 5 (see legend on next page)
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We also investigated whether stable overexpression of
LEDGF/p75 stabilized lysosomes in PC3 cells treated with
DTX for up to 48 h. Clones overexpressing LEDGF/p75
and treated with DTX appeared to have less detached or
apoptotic cells than clones transfected with empty vector
(Fig. 6), as assessed by morphological visualization of
Acridine Orange-stained cells. Attached cells overexpress-
ing LEDGF/p75 and treated with DTX exhibited stable lys-
osomes, as evidenced by the presence of cytoplasmic red
speckles and absence of yellow-colored cells. However,
visual analysis of these attached cells revealed multinucle-
ation, suggesting that ectopic overexpression of LEDGF/
p75 attenuates DTX-induced LMP and apoptosis but not
mitotic catastrophe.
Discussion
Several recent studies have established that DTX induces
tumor cell death primarily through mitotic catastrophe
and apoptosis [11-16]. However, the role of a lysosomal
pathway in DTX-induced cell death has not been thor-
oughly investigated. DTX-induced apoptosis in
melanoma and prostate cancer cells has been shown to
involve activation of caspases-2 and -3, and changes in
MMP [14,16]. Mhaidat et al [14] showed that changes in
MMP were almost completely inhibited after caspase-2
knockdown, suggesting that DTX-induced apoptosis is
dependent on caspase-2 activation [14]. Hernandez-Var-
gas et al [15] reported that the coupling of mitotic catas-
trophe with apoptosis occurs in breast cancer cells only at
0.1 μM (100 nM) concentrations, whereas very low con-
centrations of 2–4 nM induce mitotic catastrophe fol-
lowed by a late necrosis. An earlier study by Schimming
and colleagues [17] provided evidence that DTX is a
potent inducer of mitotic arrest, apoptosis, and necrotic-
like tumor cell lysis with pro-inflammatory properties in
15 syngeneic mouse xenografts.
Consistent with these previous findings, our present study
demonstrates that DTX induced mitotic catastrophe as
well as apoptosis associated with caspase-2 and -3 activa-
tion, loss of MMP, and DNA fragmentation in the HRPC
cell line PC3. The loss of MMP and the DNA fragmenta-
tion were largely caspase-dependent since they were
inhibited by Z-VAD-FMK. However, we noticed that
although inhibition of caspases-2 and -3 with Ac-VDVAD-
CHO and Z-VAD-FMK reduced DTX-induced cytotoxicity,
it did not completely block cell death, as assessed by via-
bility assays, morphological visualization, and analysis of
LMP. These results indicated that DTX-induced cell death
is not entirely dependent on caspase activation since, in
addition to mitotic catastrophe and apoptosis, it involves
a caspase-independent pathway associated with LMP.
Under our experimental conditions, DTX-induced cas-
pase-independent cell death did not appear to involve
necrosis since it was not associated with the generation of
the necrotic signature cleavage fragments of PARP and
topoisomerase 1 in cells treated with this drug in the pres-
ence of Z-VAD-FMK (Fig. 1B and data not shown). In pre-
vious reports we described the generation of necrosis-
specific fragments of PARP and topoisomerase 1 in cancer
cells undergoing primary necrosis, secondary necrosis,
and caspase-independent cell death with necrotic mor-
phology [45,50,51]. It is also unlikely that DTX-induced
caspase-independent cell death occurs through
autophagy, a stress response mechanism triggered by envi-
ronmental stressors (i.e., starvation, oxidative stress,
drugs) which often results in non-apoptotic cell death and
involves cathepsin activation and lysosomal dysfunction
[22]. We reached this conclusion after immunoblotting
analysis did not show a time-dependent upregulation in
the expression of the autophagy markers LC3bII and Bec-
lin in DTX-treated PC3 cells (data not shown).
LMP and cathepsin activation are events associated with
chemotherapy-induced cell death [48,49]. These events
occur during both caspase-dependent and independent
cell death, and involve the activation of cathepsins B, D,
and L, [48,49]. These proteases contribute to cell death by
activating effectors such as mitochondria-associated pro-
teins, caspases, apoptosis-inducing factor (AIF), or by
directly cleaving nuclear and cytoplasmic factors [48,49].
Overexpression of LEDGF/p75 attenuates DTX-induced cell death Figure 5 (see previous page)
Overexpression of LEDGF/p75 attenuates DTX-induced cell death. A. LEDGF/p75 expression in parental PC3 cells, 
pools of PC3 clones stably transfected with empty pcDNA vector (Vec), or pcDNA-ledgfp75 (p75), analyzed by immunoblot-
ting (right panel) and RT-PCR: B. Stable overexpression of LEDGF/p75 attenuated DTX-induced cytotoxicity after 36 and 48 h 
of exposure to low and high concentrations of the drug. Cell survival was determined by crystal violet staining. Data is repre-
sentative of three independent experiments. Error bars represent the standard deviation of at least three independent experi-
ments done in triplicates (* p < 0.05, t-test): C. Morphology of PC3 clones (Vec and p75) treated with DTX for 48 hours. 
Clones overexpressing LEDGF/p75 showed less dead and detached cells than clones transfected with empty vector: D. Cell 
cycle analysis of PC3 clones (Vec, and p75) treated with DTX for 48 h. Flow cytometric analysis of cells stained with propidium 
iodide was used to determine the percentage of subG1 cells. Overexpression of LEDGF/p75 significantly attenuated DTX-
induced DNA fragmentation. Representative DNA histograms are shown. Error bars represent the standard deviation of at 
least three independent experiments done in triplicates (* p < 0.05, t-test).Molecular Cancer 2009, 8:68 http://www.molecular-cancer.com/content/8/1/68
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Our data suggest that DTX-induced caspase-independent
cell death involves LMP associated with cathepsin B activ-
ity. Cathepsins D and L do not appear to contribute signif-
icantly to this process since their inhibition did not
attenuate DTX-induced cell death. These results are con-
sistent with a report implicating LMP and activation of
cathepsin B, but not cathepsin D, in caspase-independent
cell death induced by the microtubule stabilizing agents
paclitaxel, epothilone B, and discodermolide in lung can-
cer cells [19].
The release of cathepsin B from lysosomes typically fol-
lows induction of LMP by agents such as reactive oxygen
species, fatty acids, and microtubule toxins [48]. Cathep-
sin B itself can induce LMP, although the mechanisms are
unknown [48]. Once released from the lysosomes, cathe-
psin B can induce both caspase-dependent and independ-
ent cell death, as well as nuclear fragmentation [48].
Interestingly, our data show that inhibition of cathepsin B
alone is not sufficient to completely block DTX-induced
LMP and DNA fragmentation. However, inhibition of
both cathepsin B and caspases led to a dramatic reduction
of these events. These findings point to cathepsin B as a
key mediator of lysosome-mediated cell death induced by
microtubule-stabilizing drugs. They also suggest that
DTX-induced cytotoxicity involves the concerted play of
caspases and cathepsin B.
Several endogenous inhibitors of lysosome-mediated cell
death have been identified [48,49]. Among these, heat-
shock protein (Hsp) 70 family members and LEDGF/p75
have recently attracted attention due to their frequent
overexpression in tumors, and cytoprotective and chem-
oresistance properties. Daugaard et al [27] showed that
ectopic expression of LEDGF/p75 protected cancer cells
against the LMP-inducing agents siramesine and doxoru-
Overexpression of LEDGF/p75 attenuates DTX-induced LMP Figure 6
Overexpression of LEDGF/p75 attenuates DTX-induced LMP. PC3 cell clones (Vec and p75) were treated with DTX 
for up to 48 hours and stained with acridine orange (AO) to visualize LMP. Clones stably transfected with empty vector (Vec) 
showed increased LMP as indicated by minimal or absence of punctuated lysosomal red fluorescence, associated with increased 
number of detached yellow cells. Clones overexpressing LEDGF/p75 showed less cell detachment and increased lysosomal sta-
bility after DTX treatment. These resistant clones displayed extensive multinucleation.
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bicin [27]. Our data showed that ectopic overexpression
of LEDGF/p75 attenuated DTX-induced cytotoxicity and
LMP but had no effect on TRAIL-induced cell death. Over-
expression of LEDGF/p75 also attenuated DTX-induced
death in RWPE-2 cells but was not effective against TRAIL
and STS (data not shown). This suggested that LEDGF/
p75 could be a selective inhibitor of cell death, caspase-
dependent or independent, associated with LMP. Interest-
ingly, LEDGF/p75 overexpression in PC3 cells failed to
prevent DTX-induced multinucleation, suggesting that
DTX-induced mitotic catastrophe is not coupled to LMP.
The mechanisms by which LEDGF/p75 promotes lyso-
somal stability are presently unknown, although the avail-
able evidence suggests that this protein may protect cells
against oxidative stress by transcriptionally activating
stress and antioxidant genes that reduce intracellular ROS
[24-26,40,41]. A recent study showed that LEDGF/p75
physically interacts with the oncogenic transcription fac-
tor menin and the MLL histone methyltransferase to acti-
vate cancer associated genes and promote leukemic
transformation [42]. Our group is currently exploring
interactions between LEDGF/p75 and various transcrip-
tion factors to determine if this protein's ability to pro-
mote chemoresistance is associated with its capacity to
form protein complexes required for transcriptional acti-
vation of protective genes.
Conclusion
This study underscores the ability of DTX to induce con-
comitantly caspase-dependent and independent death
pathways in prostate cancer cells. Our data also point to
LEDGF/p75 as a potential contributor to prostate cancer
cell resistance to DTX-induced LMP and cell death in vitro.
The upregulation of stress and antioxidant genes is emerg-
ing as a mechanism associated with tumor chemoresist-
ance. It remains to be investigated if LEDGF/p75
overexpression in human prostate tumors contributes to
the upregulation or activity of stress/redox genes associ-
ated with cancer progression and chemoresistance. If this
turns out to be the case, LEDGF/p75, its protein interact-
ing partners, and its target genes might become attractive
candidates for molecular targeting, in combination with
DTX and other drugs, in the treatment of HRPC.
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